Bayer HealthCare and Johns Hopkins University entered into a five-year collaboration to develop ophthalmic therapies that target retinal diseases. They will work together on discovery and development of drugs for treatment of eye diseases such as age-related macular degeneration and diabetic macular edema, among others.